Blueprint
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of May 2017
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X
Form
40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __ No
X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule
12g3-2(b): 82-_____________
31 May 2017 07:00 BST
ASTRAZENECA APPOINTS PROFESSOR NAZNEEN RAHMAN
TO ITS BOARD OF DIRECTORS AND SCIENCE COMMITTEE
AstraZeneca
announced that, effective 1 June 2017, the Board has appointed
Professor Nazneen Rahman as a Non-Executive Director of AstraZeneca
PLC. On appointment, Professor Rahman also becomes a member of the
Science Committee.
Professor
Nazneen Rahman is Head of the Division of Genetics and Epidemiology
at the Institute of Cancer Research (ICR), London; Head of the
Cancer Genetics Unit at the Royal Marsden NHS Foundation Trust; and
Director of the TGL clinical gene testing laboratory at the ICR.
She qualified in medicine from Oxford University and holds a PhD in
molecular genetics.
Professor
Rahman's research harnesses her scientific and clinical expertise
to identify and clinically implement human disease genes. She has a
strong focus on cancer predisposition genes, in which she is an
internationally-recognised expert and has discovered many such
genes during her career, particularly for breast, ovarian and
childhood cancers.
Elected
as a Fellow of the Academy of Medical Sciences in 2010, Professor
Rahman is a member of the scientific advisory boards of Genomics
plc and the Centre for Molecular Medicine Norway, as well as the
advisory board of Wellcome Open Research.
Professor
Rahman has a strong commitment to open science and science
communication and has garnered numerous awards, including a CBE in
the 2016 Queen's birthday honours in recognition of her
contribution to medical sciences.
Leif
Johansson, Chairman of AstraZeneca, said: "We are delighted to
welcome Professor Rahman to our Board and Science Committee. She
brings world-renowned expertise in genetic research with a focus on
cancer, which is a strategic therapy area for our
business."
In
relation to Professor Rahman's appointment, no disclosure
obligations arise under paragraphs (1) to (6) of LR 9.6.13 R of the
UK Listing Authority's Listing Rules.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that
focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three main therapy areas - Oncology, Cardiovascular &
Metabolic Diseases and
Respiratory. The Company also is selectively active in the areas of
autoimmunity, neuroscience and infection. AstraZeneca operates in
over 100 countries and its innovative medicines are used by
millions of patients worldwide. For more information, please
visit www.astrazeneca.com and
follow us on Twitter @AstraZeneca.
Media Relations
|
|
|
Esra
Erkal-Paler
|
UK/Global
|
+44 203
749 5638
|
Karen
Birmingham
|
UK/Global
|
+44 203
749 5634
|
Rob
Skelding
|
UK/Global
|
+44 203
749 5821
|
Jacob
Lund
|
Sweden
|
+46
8 553 260 20
|
Michele
Meixell
|
US
|
+1 302
885 2677
|
Investor
Relations
|
|
|
Thomas
Kudsk Larsen
|
|
+44 203
749 5712
|
Craig
Marks
|
Finance,
Fixed Income, M&A
|
+44
7881 615 764
|
Henry
Wheeler
|
Oncology
|
+44 203
749 5797
|
Mitchell
Chan
|
Oncology
|
+1 240
477 3771
|
Lindsey
Trickett
|
Cardiovascular
& Metabolic Diseases
|
+1 240
543 7970
|
Nick
Stone
|
Respiratory
|
+44 203
749 5716
|
Christer
Gruvris
|
Autoimmunity,
Neuroscience & Infection
|
+44 203
749 5711
|
US toll
free
|
|
+1 866
381 7277
|
Adrian Kemp
Company Secretary, AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
AstraZeneca
PLC
Date:
31 May 2017
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|